Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2012 | short review | Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012

ASH 2011—current developments in AML

memo - Magazine of European Medical Oncology > Ausgabe 3/2012
M.D. Johannes Clausen


Treatment strategies for acute myelogenous leukemia (AML) will be increasingly directed by molecular and cytogenetic disease features. However, drugs targeting single molecular checkpoints have shown limited success in AML. Thus, cytotoxic chemotherapy and allogeneic stem cell transplantation remain the mainstay of AML therapy, besides the emerging role of epigenetic concepts mainly represented by hypomethylating compounds. Therefore, cooperative concepts are needed in the future, integrating both cytotoreductive and molecular-targeted, as well as immunotherapeutic treatment approaches. To come up to the complexity of both molecular pathomechanisms and resulting treatment modalities, patients with AML should be treated within appropriately designed clinical studies whenever possible.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe